KRAS G12C: The Mutation You Thought You Knew
Six reasons the KRAS G12C mutation matters
sponsored by Amgen Oncology
To learn more about Amgen’s work in KRAS G12C and the importance of biomarker testing visit FindKRASG12C.com.
- I Ferrer et al., Lung Cancer, 124, 53 (2018). PMID: 30268480.
- M Nagasaka et al., Cancer Treat Rev, 84, 101974 (2020). PMID: 32014824.
- NT Ihle et al., J Natl Cancer Inst, 104, 228 (2012). PMID: 22247021.
- Amgen, Data on file (Analysis of AACR Genie v8).
- S Pakkala, SS Ramalingam, JCI Insight, 3, e120858 (2018). PMID: 30089719.
- J Canon et al., Nature, 575, 217 (2019). PMID: 31666701.
- JML Ostrem, KM Shokat, Nat Rev Drug Discov, 15, 771 (2016). PMID: 27469033.
- NA Pennell et al., Am Soc Clin Oncol Educ Book, 39, 531 (2019). PMID: 31099633.
- GP Kalemkerian et al., J Clin Oncol, 36, 911 (2018). PMID: 29401004.
- NI Lindeman et al., Arch Pathol Lab Med, 142, 321 (2018). PMID: 29355391.
- C Rolfo et al., J Thorac Oncol, 13, 1248 (2018). PMID: 29885479.
- S Aggarwal et al. Presented at the European Society for Medical Oncology; September
19–21, 2020. Abstract #1339P. - T Ahmadzada et al., J Clin Med, 7, 153 (2018). PMID: 29914100.
- Foundation Medicine. Available at: https://bit.ly/3e3fxws.
- NB Leighl et al., Clin Cancer Res, 25, 4691 (2019). PMID: 30988079.